Belite Bio (BLTE) Projected to Release Earnings on Monday

Key Points

• Belite Bio is expected to report Q3 2026 results after the market closes on November 9, with analysts forecasting a loss of $0.7863 per share. Analysts project full-year EPS of -$3.08 and next-year EPS of $0.91.
• BLTE opened at $154.74, giving the company a market capitalization of approximately $6.23 billion. The stock has traded between $97.99 and $200.00 over the past year.
• Analyst sentiment is broadly positive, with a consensus rating of “Moderate Buy” and an average price target of $227.40, although insiders sold 169,062 shares worth about $32.1 million in the latest quarter.

Belite Bio (NASDAQ:BLTE - Get Free Report) is projected to post its Q3 2026 results after the market closes on Monday, November 9th. Analysts expect the company to post earnings of ($0.7863) per share for the quarter. Individuals are encouraged to explore the company's upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Monday, November 9, 2026 at 4:30 PM ET.

Belite Bio (NASDAQ:BLTE - Get Free Report) last issued its earnings results on Tuesday, June 30th. The company reported ($0.54) earnings per share for the quarter. On average, analysts expect Belite Bio to post ($3.08) EPS for the current fiscal year and $0.91 EPS for the next fiscal year.

Belite Bio Price Performance

NASDAQ:BLTE opened at $154.74 on Monday. The firm has a 50-day moving average price of $161.47 and a 200 day moving average price of $160.37. The firm has a market capitalization of $6.23 billion, a PE ratio of -56.68 and a beta of -1.19. Belite Bio has a 12-month low of $97.99 and a 12-month high of $200.00.

Analyst Ratings Changes

A number of research analysts have commented on BLTE shares. HC Wainwright reiterated a "buy" rating and issued a $245.00 price objective on shares of Belite Bio in a research report on Thursday, October 15th. Weiss Ratings reissued a "sell (d-)" rating on shares of Belite Bio in a research report on Friday, October 2nd. Benchmark reissued a "buy" rating on shares of Belite Bio in a research note on Friday, August 14th. Mizuho raised their price objective on shares of Belite Bio from $220.00 to $234.00 and gave the stock an "outperform" rating in a report on Wednesday, September 9th. Finally, Morgan Stanley upped their target price on shares of Belite Bio from $201.00 to $206.00 and gave the stock an "overweight" rating in a research note on Friday, August 14th. Eight research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $227.40.

Insider Activity

In related news, insider Hendrik Scholl sold 500 shares of the company's stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $165.32, for a total transaction of $82,660.00. Following the sale, the insider owned 14,500 shares in the company, valued at approximately $2,397,140. This represents a 3.33% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Hao-Yuan Chuang sold 49,433 shares of the firm's stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $187.64, for a total value of $9,275,608.12. Following the completion of the transaction, the chief financial officer owned 44,000 shares of the company's stock, valued at approximately $8,256,160. This represents a 52.91% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 169,062 shares of company stock worth $32,101,134 in the last quarter. Corporate insiders own 13.29% of the company's stock.

Belite Bio Company Profile

Belite Bio, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for eye diseases that can cause severe vision loss. The company's research is centered on therapies that target the visual cycle, a biological process involved in the production and recycling of vitamin A in the retina.

Belite Bio's lead product candidate is tinlarebant, also known as LBS-008. The orally administered therapy is designed to reduce the formation and accumulation of toxic vitamin A byproducts in the eye.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.